Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples
Daniel Saarela,Pawel Lis,Sara Gomes,Raja S. Nirujogi,Wentao Dong,Eshaan Rawat,Sophie Glendinning,Karolina Zeneviciute,Enrico Bagnoli,Rotimi Fasimoye,Cindy Lin,Kwamina Nyame,Fanni A. Boros,Friederike Zunke,Frederic Lamoliatte,Sadik Elshani,Matthew Jaconnelli,Judith J. M. Jans,Margriet A. Huisman,Christian Posern,Lena M. Westermann,Angela Schulz,Peter M. van Hasselt,Dario R. Alessi,Monther Abu-Remaileh,Esther Sammler
DOI: https://doi.org/10.1101/2024.05.17.594681
2024-05-27
Abstract:Lysosomes are implicated in a wide spectrum of human diseases including monogenic lysosomal storage disorders (LSDs), age-associated neurodegeneration and cancer. Profiling lysosomal content using tag-based lysosomal immunoprecipitation (LysoTagIP) in cell and animal models allowed major discoveries in the field, however studying lysosomal dysfunction in human patients remains challenging. Here, we report the development of the tagless LysoIP method to enable rapid enrichment of lysosomes, via immunoprecipitation, using the endogenous integral lysosomal membrane protein TMEM192, directly from clinical samples and human cell lines (e.g. induced Pluripotent Stem Cell (iPSCs) derived neurons). Isolated lysosomes are intact and suitable for subsequent multimodal omics analyses. To validate our approach, we employed the tagless LysoIP to enrich lysosomes from peripheral blood mononuclear cells (PBMCs) derived from fresh blood of patients with CLN3 disease, a neurodegenerative LSD. Metabolic profiling of isolated lysosomes showed massive accumulation of glycerophosphodiesters (GPDs) in patients' lysosomes. Interestingly, a patient with a milder phenotype and genotype displayed lower accumulation of lysosomal GPDs, consistent with their potential role as disease biomarkers. Altogether, the tagless LysoIP provides a framework to study native lysosomes from patient samples, identify novel biomarkers and discover human-relevant disease mechanisms.
Cell Biology